For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the ...

The use of anticoagulants offers significant benefits. They are indicated for various uses depending on the specific anticoagulant used, including: These medications protect individuals at high ...

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K ...

TAIPEI, Jan. 21, 2025 /CNW/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Age, anticoagulant use, hypertension, and genetic cardiovascular (CV) traits may predict the risk for cranial ischemic complications among patients with giant cell arteritis (GCA), according to ...

Assembly Bill 2552 now awaits state Senate approval. Authored by Assemblymember Laura Friedman, A.B. 2552 would expand the existing rat poison moratorium to include first-generation anticoagulant ...